目的通过观察心脏死亡器官捐献(Donation after Cardiac Death,DCD)移植器官的临床结果,探讨DCD移植的可行性和注意事项。方法对华中科技大学同济医学院附属同济医院2010年3月至2012年10月期间施行的DCD移植器官的临床资料进行回顾性总...目的通过观察心脏死亡器官捐献(Donation after Cardiac Death,DCD)移植器官的临床结果,探讨DCD移植的可行性和注意事项。方法对华中科技大学同济医学院附属同济医院2010年3月至2012年10月期间施行的DCD移植器官的临床资料进行回顾性总结。结果共有13例受者纳入研究,包括8例肾移植和5例肝移植,手术顺利。肾移植病例中术后分别因移植肾动脉破裂、急性抗体介导的排斥反应(AAMR)而切除移植肾2例,因脑血管意外死亡1例。肝移植病例中因肝动脉出血死亡1例。总体1年移植物/人存活率分别为69.2%和84.6%。结论使用DCD捐献器官可以扩大供体来源,缓解器官短缺困难,但应注意并发症发生,提高移植效果。展开更多
Aim To investigate the mechanism of anti-CD132 monoclonal antibodies (mAbs)inhibiting T cells proliferation in vitro, and their potential values for clinical use. MethodsBALB/c and C57BL/6 mice splenocytes were harves...Aim To investigate the mechanism of anti-CD132 monoclonal antibodies (mAbs)inhibiting T cells proliferation in vitro, and their potential values for clinical use. MethodsBALB/c and C57BL/6 mice splenocytes were harvested for two-ways mixed lymphocyte culture (MLC).Anti-CD132 mAbs (final concentration 100 mg·L^(-1)) were added in MLC on day 0 (group 1) or day 3(group 2). Fluorescence activated cell sorting (FACS) was used to measure the proliferation(carboxy-fluorescein dia cetate, succinimidyl ester, CFSE), apoptosis of T cells (PE-CD3,FTTC-annexin-v), and cell cycle (pro-pidium iodide stain) . The expression of survivin in T cellswas detected by immunochemical stai-ning. Re-sults Multi-generation CFSE-labeled splenocytes werefound dividing and their fluorescent strength decreased in MLC. There was no noticeable change influorescent intensity in group 1 and group 2. On day 3, apoptosis induced by anti-CD132 mAbs wasdetected in part of T cells, but was not detected in the former two days in group 1. In group 2, thenumber of cells in M phase (activated T cells) decreased and apoptot-ic cells increased on day 4.The phenomena were not observed in control group (P < 0.01). Expression of survivin in T cells wasdetected in control group but not in groups 1 and 2. Conclusion Blockade of CD132 signaling pathwayinhibits T cell proliferation in vitro by means of inducing activated alloreactive T cell apoptosisbut not the resting T cells. Anti-CD132 mAbs may be candidates for clinical applications.展开更多
文摘目的通过观察心脏死亡器官捐献(Donation after Cardiac Death,DCD)移植器官的临床结果,探讨DCD移植的可行性和注意事项。方法对华中科技大学同济医学院附属同济医院2010年3月至2012年10月期间施行的DCD移植器官的临床资料进行回顾性总结。结果共有13例受者纳入研究,包括8例肾移植和5例肝移植,手术顺利。肾移植病例中术后分别因移植肾动脉破裂、急性抗体介导的排斥反应(AAMR)而切除移植肾2例,因脑血管意外死亡1例。肝移植病例中因肝动脉出血死亡1例。总体1年移植物/人存活率分别为69.2%和84.6%。结论使用DCD捐献器官可以扩大供体来源,缓解器官短缺困难,但应注意并发症发生,提高移植效果。
基金National Basic Research Program of China (973 Pro gram, No.2003CB515505) National Natural Science Foundation of China (No.30271243)
文摘Aim To investigate the mechanism of anti-CD132 monoclonal antibodies (mAbs)inhibiting T cells proliferation in vitro, and their potential values for clinical use. MethodsBALB/c and C57BL/6 mice splenocytes were harvested for two-ways mixed lymphocyte culture (MLC).Anti-CD132 mAbs (final concentration 100 mg·L^(-1)) were added in MLC on day 0 (group 1) or day 3(group 2). Fluorescence activated cell sorting (FACS) was used to measure the proliferation(carboxy-fluorescein dia cetate, succinimidyl ester, CFSE), apoptosis of T cells (PE-CD3,FTTC-annexin-v), and cell cycle (pro-pidium iodide stain) . The expression of survivin in T cellswas detected by immunochemical stai-ning. Re-sults Multi-generation CFSE-labeled splenocytes werefound dividing and their fluorescent strength decreased in MLC. There was no noticeable change influorescent intensity in group 1 and group 2. On day 3, apoptosis induced by anti-CD132 mAbs wasdetected in part of T cells, but was not detected in the former two days in group 1. In group 2, thenumber of cells in M phase (activated T cells) decreased and apoptot-ic cells increased on day 4.The phenomena were not observed in control group (P < 0.01). Expression of survivin in T cells wasdetected in control group but not in groups 1 and 2. Conclusion Blockade of CD132 signaling pathwayinhibits T cell proliferation in vitro by means of inducing activated alloreactive T cell apoptosisbut not the resting T cells. Anti-CD132 mAbs may be candidates for clinical applications.
